Moreover, there may be significant opportunity costs associated with regulatory and reimbursement decisions for new technologies informed by misleading findings from mapping studies.
← all excerpts
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement.
1
—
—